Glucagon Market Report Probes the USD Million Size, Share, Growth Report and Future Analysis by 2033

Key Insights

The Glucagon Market size was valued at USD 278.5 USD Million in 2023 and is projected to reach USD 441.39 USD Million by 2032, exhibiting a CAGR of 6.8 % during the forecast period. When the levels of glucose in the blood become too low, Glucagon, a peptide hormone produced by the pancreas, activates the release of glucose from the liver to maintain a normal level of blood sugar. It has two primary types: glucagon-\alpha and -\beta. In cases where glucose levels dip due to fasting or hypoglycemia, alpha glucagon promotes the conversion of stored glycogen in the liver into glucose, easing the release of the product back into the bloodstream to boost glucose levels. Gamma-glucagon also plays an important role in digestion by acting on the release of gastric acid and enzymes. With respect to physical function, synthetic glucagon, besides medicine, has a variety of functions, primarily, in the treatment of severe hypoglycemia, an emergency situation that occurs in patients with diabetes with low blood sugar

Glucagon Trends

• Increasing prevalence of diabetes
• Growing awareness about glucagon therapy
• Technological advancements in glucagon delivery systems

Driving Forces: What's Propelling the Glucagon Market

• Soaring Prevalence of Diabetes and Hypoglycemia: The global surge in type 1 and type 2 diabetes significantly increases the risk of severe hypoglycemic events, creating a substantial and growing need for readily available glucagon treatment. This is further amplified by the increasing prevalence of prediabetes, expanding the potential patient population.
• Robust Government Initiatives and Healthcare Policies: Governments worldwide are prioritizing diabetes management through various initiatives. These include not only expanding access to glucagon but also investing in public awareness campaigns, educational programs, and reimbursement policies designed to make this life-saving medication more affordable and accessible. This proactive approach is a key driver of market expansion.
• Innovation in Glucagon Delivery Systems: Continuous advancements in glucagon delivery technologies are revolutionizing patient care. The development of more convenient and user-friendly administration methods, such as pre-filled pens and auto-injectors, is improving patient compliance and broadening the accessibility of glucagon therapy, particularly for those managing their condition independently.
• Enhanced Patient Education and Awareness: Targeted educational campaigns and the rise of patient advocacy groups are playing a vital role in increasing awareness of hypoglycemia and the critical role glucagon plays in managing it. Better informed patients are more likely to seek appropriate treatment and advocate for access to this essential medication.
• Improved Access and Reimbursement Strategies: The inclusion of glucagon in national formularies and the implementation of favorable reimbursement policies are significantly impacting market growth. By reducing financial barriers, these initiatives ensure timely access to glucagon for a wider patient population, ultimately leading to improved health outcomes.

Challenges and Restraints in Glucagon Market

• High cost of glucagon therapy, hindering affordability for patients and healthcare systems.
• Availability of alternative treatments for hypoglycemia, such as oral glucose or injectable dextrose, creating competition in the market.
• Limited access to glucagon in developing countries, due to factors such as lack of infrastructure, distribution challenges, and socio-economic barriers.

Emerging Trends in Glucagon

• Development of nasal glucagon products
• Advances in continuous glucose monitoring systems
• Growing adoption of telemedicine for glucagon management

Growth Catalysts in Glucagon Industry

• Increasing adoption of glucagon in emergency situations, particularly in settings where rapid reversal of hypoglycemia is crucial, such as hospitals and clinics.
• Rising demand for self-injectable glucagon devices, providing convenience and ease of administration for patients with diabetes.
• Government reimbursement policies supporting glucagon therapy, expanding access to treatment and reducing out-of-pocket costs for patients.

Market Segmentation: Glucagon Analysis

Route of Administration:

• Injectable
• Inhalation

Application:

• Hypoglycemia
• Diagnostic Aid

Distribution Channel:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Leading Players in the Glucagon Market

• Novo Nordisk A/S
• Fresenius SE & Co. KGaA
• Amphastar Pharmaceuticals, Inc.
• Xeris Biopharma Holdings, Inc.
• ILS Inc.
• United Biotech (P) Limited
• Zealand Pharma A/S
• Taj Pharmaceuticals Limited

Significant Developments in the Glucagon Sector

• June 2023: Amphastar Pharmaceuticals, Inc. acquired BAQSIMI from Eli Lilly and Company.
• November 2022: Tetris Pharma Ltd. launched Ogluo in Germany.
• March 2021: Zealand Pharma received approval for Zegalogue from the U.S. FDA.
• January 2021: Baqsimi received marketing authorization from the European Commission.
• December 2020: Amphastar Pharmaceuticals, Inc. received approval for its new drug application of glucagon for Injection Emergency Kit.

Comprehensive Coverage Glucagon Market Report

This report provides comprehensive insights into the glucagon market, including:

• Market size and forecast: Detailed analysis of the current market size and projections for future growth.
• Competitive landscape: Assessment of key players, their market share, product offerings, and competitive strategies.
• Product analysis: Evaluation of different types of glucagon products, their indications, efficacy, and safety profiles.
• Regional analysis: Examination of market trends and growth opportunities in various geographic regions.
• Emerging trends: Identification of innovative technologies, new product developments, and emerging market dynamics.
• Growth drivers and challenges: In-depth analysis of factors influencing market growth and potential barriers to adoption.

Regional Insight

• North America: Remains the dominant market, fueled by high diabetes prevalence, well-established healthcare infrastructure, and robust pharmaceutical development and marketing activities.
• Europe: A substantial market characterized by favorable reimbursement policies, a strong emphasis on preventative healthcare, and a well-developed distribution network for pharmaceutical products.
• Asia Pacific: Experiencing rapid market expansion due to the escalating incidence of diabetes, particularly in rapidly developing economies. Government initiatives focused on improving healthcare access and affordability are contributing significantly to market growth.
• Latin America: An emerging market with considerable growth potential. However, future market penetration hinges on continued investment in healthcare infrastructure development and improved access to essential medications.
• Middle East and Africa: While currently a smaller market segment, the rising prevalence of diabetes and increasing economic development in certain regions are expected to drive future growth in demand for glucagon.

DROCT

• Drivers: Increasing diabetes prevalence, technological advancements
• Restraints: High cost of therapy
• Opportunities: Emerging markets, new product development
• Challenges: Access to glucagon in developing countries
• Threats: Alternative treatments for hypoglycemia

Pricing Analysis

Factors influencing glucagon pricing:

• Manufacturing costs
• Research and development expenses
• Competition
• Regulatory approvals

Import And Export Analysis

Major import and export countries:

• United States
• Europe
• China
• India

Segmentation

By Route of Administration

• Injectable
• Inhalation

By Application

• Hypoglycemia
• Diagnostic Aid

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies